IP Verse

Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression Innpm1

Patent No. EP3407884 (titled "Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression Innpm1") was filed by Memorial Sloan Kettering Cancer Center on Jan 26, 2017. The application was issued on Jul 9, 2025.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
STRAWMANJan 7, 2026HOFFMANN EITLE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3407884

MEMORIAL SLOAN KETTERING CANCER CENTER
Application Number
EP17744904A
Filing Date
Jan 26, 2017
Status
Granted And Under Opposition
Jun 6, 2025
Publication Date
Jul 9, 2025
External Links
Slate, Register , Google Patents